Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR | Market Cap | 1.93B -38.6% |
| Revenue (ttm) | 2.03B +8.7% |
| Net Income | 104.58M -22.5% |
| EPS | 1.36 -22.9% |
| Shares Out | 76.63M |
| PE Ratio | 18.48 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,817 |
| Average Volume | 143,307 |
| Open | 26.94 |
| Previous Close | 26.23 |
| Day's Range | 25.00 - 26.94 |
| 52-Week Range | 23.12 - 42.00 |
| Beta | -0.27 |
| RSI | 43.80 |
| Earnings Date | May 22, 2026 |
About BOM:500009
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Am... [Read more]
Financial Performance
In fiscal year 2025, BOM:500009's revenue was 1.97 billion, an increase of 13.20% compared to the previous year's 1.74 billion. Earnings were 49.31 million, a decrease of -13.20%.
Financial StatementsNews
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...